Literature DB >> 3061681

Antithrombin-III prevents the lethal effects of Escherichia coli infusion in baboons.

F B Taylor1, T E Emerson, R Jordan, A K Chang, K E Blick.   

Abstract

Infusion of Escherichia coli (LD100) was followed by coagulopathic and cell injury responses, cardiovascular collapse, and death in 18 to 32 hr in four out of four baboons. Infusion of AT-III in sufficient amounts to achieve AT-III levels of more than 4 units/ml of plasma before and during the infusion of E. coli reduced the intensity of the coagulopathic and cell injury response and prevented vascular collapse and death in four out of four baboons. Failure to achieve AT-III levels of more than six units/ml at T +60 min during the infusion of E. coli resulted in failure to prevent its lethal effects in three out of three baboons even though levels as high as 10 units/ml were achieved later in the course of the experiment. These studies suggest that thrombin and/or its products can contribute to the inflammatory response to E. coli and that AT-III is of potential value as a prophylactic but not as a therapeutic agent in the treatment of patients at high risk of developing gram negative sepsis.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3061681

Source DB:  PubMed          Journal:  Circ Shock        ISSN: 0092-6213


  31 in total

Review 1.  [Microcirculation and hemostasis in inflammatory processes. Modulation by administration of physiologic protease inhibitors as a therapeutic approach].

Authors:  B Leithäuser; F R Matthias
Journal:  Med Klin (Munich)       Date:  1997-07-15

Review 2.  Differential Paradigms in Animal Models of Sepsis.

Authors:  S Manoj Kumar Kingsley; B Vishnu Bhat
Journal:  Curr Infect Dis Rep       Date:  2016-09       Impact factor: 3.725

Review 3.  Recombinant natural anticoagulants: a review.

Authors:  P L Harper; J M Hermans; R W Carrell
Journal:  J R Soc Med       Date:  1992-07       Impact factor: 5.344

4.  Thrombin-thrombomodulin connects coagulation and fibrinolysis: more than an in vitro phenomenon.

Authors:  Tanya M Binette; Fletcher B Taylor; Glenn Peer; Laszlo Bajzar
Journal:  Blood       Date:  2007-07-20       Impact factor: 22.113

5.  Recommendations for the use of antithrombin concentrates and prothrombin complex concentrates.

Authors:  Giancarlo Liumbruno; Francesco Bennardello; Angela Lattanzio; Pierluigi Piccoli; Gina Rossetti
Journal:  Blood Transfus       Date:  2009-10       Impact factor: 3.443

Review 6.  The loss of homeostasis in hemostasis: new approaches in treating and understanding acute disseminated intravascular coagulation in critically ill patients.

Authors:  Karen M Hook; Charles S Abrams
Journal:  Clin Transl Sci       Date:  2011-12-07       Impact factor: 4.689

7.  Antithrombin III in patients with severe sepsis. A randomized, placebo-controlled, double-blind multicenter trial plus a meta-analysis on all randomized, placebo-controlled, double-blind trials with antithrombin III in severe sepsis.

Authors:  B Eisele; M Lamy; L G Thijs; H O Keinecke; H P Schuster; F R Matthias; F Fourrier; H Heinrichs; U Delvos
Journal:  Intensive Care Med       Date:  1998-07       Impact factor: 17.440

8.  Use of antithrombin III in critical patients.

Authors:  J M Díaz-Cremades; R Lorenzo; M Sánchez; M J Moreno; M J Alsar; J M Bosch; L Fajardo; D González; D Guerrero
Journal:  Intensive Care Med       Date:  1994-11       Impact factor: 17.440

9.  Fondaparinux pentasaccharide reduces sepsis coagulopathy and promotes survival in the baboon model of Escherichia coli sepsis.

Authors:  Ravi S Keshari; Robert Silasi; Narcis I Popescu; Constantin Georgescu; Hala Chaaban; Cristina Lupu; Owen J T McCarty; Charles T Esmon; Florea Lupu
Journal:  J Thromb Haemost       Date:  2019-10-16       Impact factor: 5.824

10.  Activation of the complement system in baboons challenged with live Escherichia coli: correlation with mortality and evidence for a biphasic activation pattern.

Authors:  J P de Boer; A A Creasey; A Chang; D Roem; A J Eerenberg; C E Hack; F B Taylor
Journal:  Infect Immun       Date:  1993-10       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.